PMID- 14626291
OWN - NLM
STAT- MEDLINE
DCOM- 20040223
LR  - 20190911
IS  - 0300-7995 (Print)
IS  - 0300-7995 (Linking)
VI  - 19
IP  - 7
DP  - 2003
TI  - The tolerability of viscosupplementation: low incidence and clinical management 
      of local adverse events.
PG  - 575-80
AB  - Hylan G-F 20 (Synvisc, Genzyme Biosurgery, Ridgefield, NJ) is a visco supplement 
      indicated for the treatment of pain due to osteoarthritis (OA) of the knee. 
      Overall, the therapy is well tolerated with a low incidence of local and systemic 
      adverse events (AEs). In our large clinical practice, our overall rate of local 
      pain and swelling with treatment is consistent with that of previous reports and 
      the product labeling. Local AEs that do occur with therapy are mostly mild to 
      moderate in nature, transient, and resolve spontaneously or with symptomatic 
      treatment. Local AEs thought to be related to the treatment are clinically 
      manageable and do not result in long-term sequelae, such that their occurrence 
      should not preclude patients from the benefit of OA pain relief with therapy, 
      including continued pain relief with repeat treatment. Based on previous 
      published reports of hylan G-F 20 and our extensive clinical experience, relief 
      of OA knee pain with hylan G-F 20 far outweighs the low risk of local AEs for 
      patients who do not respond to other therapies indicated for the treatment of OA 
      knee pain.
FAU - Waddell, David D
AU  - Waddell DD
AD  - Orthopedic Specialists of Louisiana, Shreveport 71103, USA. oslresearch@aol.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 125935-84-4 (hylan)
RN  - 9004-61-9 (Hyaluronic Acid)
SB  - IM
MH  - Humans
MH  - Hyaluronic Acid/*administration & dosage/*adverse effects/*analogs & derivatives
MH  - Incidence
MH  - Injections, Intra-Articular
MH  - Osteoarthritis, Knee/*drug therapy/physiopathology
MH  - Pain/*drug therapy
RF  - 50
EDAT- 2003/11/25 05:00
MHDA- 2004/02/24 05:00
CRDT- 2003/11/25 05:00
PHST- 2003/11/25 05:00 [pubmed]
PHST- 2004/02/24 05:00 [medline]
PHST- 2003/11/25 05:00 [entrez]
AID - 10.1185/030079903125002243 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2003;19(7):575-80. doi: 10.1185/030079903125002243.